

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### Meeting Notice for the President's Advisory Council on Faith-Based and Neighborhood Partnerships

In accordance with section 10(a)(2) of the Federal Advisory Committee Act (Pub. L. 92-463), the President's Advisory Council on Faith-based and Neighborhood Partnerships announces the following webinar:

*Name:* President's Advisory Council on Faith-based and Neighborhood Partnerships Council Meetings

*Time and Date:* Wednesday, June 22, 2016 3:00 p.m.–5:00 p.m. (EDT)

*Public Webinar:* The conference call will be available to the public through a webinar system. Register to participate in the conference call on Wednesday, June 22 at the Web site <https://attendee.gotowebinar.com/register/2826503921415476996>

*Status:* Conference call limited only by lines available.

*Purpose:* The Council brings together leaders and experts in fields related to the work of faith-based and neighborhood organizations in order to: Identify best practices and successful modes of delivering social services; evaluate the need for improvements in the implementation and coordination of public policies relating to faith-based and other neighborhood organizations; and make recommendations for changes in policies, programs, and practices. The charge for this Council focuses on steps the government should take to reduce poverty and inequality and create opportunity for all, including changes in policies, programs, and practices that affect the delivery of services by faith-based and community organizations and the needs of low-income and other underserved persons.

*Contact Person for Additional Information:* Please contact Ben O'Dell for any additional information about the President's Advisory Council meeting at [partnerships@hhs.gov](mailto:partnerships@hhs.gov)

*Agenda:* Opening and Welcome from the Chairperson and Executive Director for the President's Advisory Council for Faith-based and Neighborhood Partnership; Presentation of additional language and recommendations for the report; Deliberation of recommendations (if necessary); Conclusion from Chairperson and Executive Director

*Public Comment:* There will be an opportunity for public comment at the end of the meeting. Desire to make comments and questions should be sent in advance to [partnerships@hhs.gov](mailto:partnerships@hhs.gov).

Dated: June 2, 2016.

**Ben O'Dell,**

*Associate Director for Center for Faith-based and Neighborhood Partnerships at U.S. Department of Health and Human Services.*

[FR Doc. 2016-13540 Filed 6-7-16; 8:45 am]

**BILLING CODE 4154-07-P**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### Office of the Secretary

#### Findings of Research Misconduct

**AGENCY:** Office of the Secretary, HHS.

**ACTION:** Notice.

**SUMMARY:** Notice is hereby given that the Office of Research Integrity (ORI) has taken final action in the following case:

*Meredyth M. Forbes, Albert Einstein College of Medicine:* Based on an assessment conducted by the Albert Einstein College of Medicine (AECM), an admission from the Respondent, and additional analysis conducted by ORI in its oversight review, ORI found that Ms. Meredyth M. Forbes, former Graduate Student, AECM, engaged in research misconduct in research supported by National Institute of General Medical Sciences (NIGMS), National Institutes of Health (NIH), grants R01 GM089979, T32 GM007491, R01 GM55101, and R01 GM88202 and National Institute of Child Health and Human Development (NICHD), NIH, grant T32 HD007502.

ORI found that Respondent engaged in research misconduct by intentionally falsifying and/or fabricating data reported in the following three (3) published papers and four (4) meeting presentations:

- *Development.* In press, published online, Dec 23, 2015; doi:10.1242/dev.129023 (hereafter referred to as the "December 2015 *Development* paper")
- *Cell Reports* 12:49–57, 2015 (hereafter referred to as the "*Cell Reports* paper")
- *Development* 142(15):2704–18, 2015 Aug 1 (hereafter referred to as the "August 2015 *Development* paper")
- "Maternal *dazap2* regulates germ granules via counteracting Dynein in zebrafish primordial germ cells." Laboratory Presentation, January 28, 2015 (hereafter referred to as the "*Lab Presentation* 2015")
- "Maternal *dazap2* regulates germ granule formation in zebrafish primordial germ cells." Presented at the Germ Cells, Cold Spring Harbor, NY, October 2014, NYC-Wide Stem Cell Event, "Stem Cells in the City," NY, November 2014, Mid-Atlantic Regional Zebrafish Meeting, PA, November 2014, and New York Metropolitan Zebrafish Meeting, Cornell, NY, January 2015 (hereafter referred to as "*Poster* 1, 2014–2015")
- "Cytoskeleton, microtubules, centrosomes, germline cyst, Bucky ball, oocytes." Poster presented at the

Mid-Atlantic Regional Zebrafish Meeting, Bronx, NY, July 2015 (hereafter referred to as "*MARZ* 2015")

- "Bucky ball associates with the centrosome and promotes microtubule cytoskeleton rearrangements to establish oocyte polarity in zebrafish." Poster presented at the American Society for Cell Biology (ASCB) Meeting, San Diego, CA, December 2015 (hereafter referred to as "*ACSB* 2015")

ORI found that Respondent intentionally falsified and/or fabricated data for germ-cell development in zebrafish *Dazap2* maternal-effect mutants (MDazap2) in one (1) paper and two (2) presentations when the mutants were not produced nor the data derived from them.

Specifically, Respondent:

- falsified thirty-eight (38) fluorescent image panels by drawing staining in PhotoShop and falsely labeling them in Figures 1F, 1G, 2A, 2C, 2E, 2F, 2G, 3A, 3D, 4A, and S2A in the *Cell Reports* paper and included some of the same images in seven (7) figures in *Lab Presentation* 2015 and in six (6) figures in *Poster* 1 2014–2015
- fabricated numbers for data presented in ten (10) graphs in Figures 1L, 2B, 2D, 2H, 3B, 4B, 4C, S2B, S2C, and S3B in the *Cell Reports* paper and included some of the same graphs in seven (7) figures in *Lab Presentation* 2015 and in six (6) figures in *Poster* 1 2014–2015

ORI found that Respondent intentionally fabricated and/or falsified data for zebrafish embryogenesis and oocyte polarity in two (2) papers and two (2) presentations when the data were not obtained from actual experiments.

Specifically, Respondent:

- falsified twenty-four (24) fluorescent image panels by drawing staining in Photoshop and falsely labeling them in Figures 5B, 5C, 5D, 5E, 7A, 7B, 7D, 8A, 8B, 9A, and 9B in the August 2015 *Development* paper and included some of the same images in four (4) figures in the *ASCB* 2015 poster and in two (2) figures in the *MARZ* 2015 poster
- fabricated numbers for data presented in eight (8) graphs and one (1) illustration in Figures 5F, 7C, 7E, 8C, 8F–I, 9C, and 9D in the December 2015 *Development* paper and Figure 2F in the August 2015 *Development* paper and included some of the same graphs in four (4) figures in the *ASCB* 2015 poster and in two (2) figures in the *MARZ* 2015 poster

Ms. Forbes has entered into a Voluntary Exclusion Agreement (Agreement) and has voluntarily agreed for a period of three (3) years, beginning on May 6, 2016:

(1) to exclude herself from any contracting or subcontracting with any agency of the United States Government and from eligibility or involvement in nonprocurement programs of the United States Government referred to as "covered transactions" pursuant to HHS' Implementation (2 CFR part 376 *et seq.*) of OMB Guidelines to Agencies on Governmentwide Debarment and Suspension, 2 CFR part 180 (collectively the "Debarment Regulations");

(2) that she will neither apply for nor permit her name to be used on any application, proposal, or other request for funds to the United States Government or any of its agencies, as defined in the Debarment Regulations; Respondent will further ensure that during the period of the voluntary exclusion, she will neither receive nor be supported by funds of the United States Government and its agencies made available through grants, subgrants, cooperative agreements, contracts, or subcontracts, as discussed in the Debarment Regulations; and

(3) to exclude herself from serving in any advisory capacity to the U.S. Public Health Service (PHS) including, but not limited to, service on any PHS advisory committee, board, and/or peer review committee, or as a consultant.

**FOR FURTHER INFORMATION CONTACT:** Director, Office of Research Integrity, 1101 Wootton Parkway, Suite 750, Rockville, MD 20852, (240) 453-8200.

**Kathryn M. Partin,**

*Director, Office of Research Integrity.*

[FR Doc. 2016-13541 Filed 6-7-16; 8:45 am]

**BILLING CODE 4150-31-P**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### Meeting of the Advisory Group on Prevention, Health Promotion, and Integrative and Public Health

**AGENCY:** Office of the Surgeon General of the United States Public Health Service, Office of the Assistant Secretary for Health, Office of the Secretary, Department of Health and Human Services.

**ACTION:** Notice.

**SUMMARY:** In accordance with Section 10(a) of the Federal Advisory Committee Act, Public Law 92-463, as amended (5 U.S.C. App.), notice is hereby given that a meeting is scheduled for the Advisory Group on Prevention, Health Promotion,

and Integrative and Public Health (the "Advisory Group"). This meeting will be open to the public. Information about the Advisory Group and the agenda for this meeting can be obtained by accessing the following Web site: <http://www.surgeongeneral.gov/priorities/prevention/advisorygrp/index.html>.

**DATES:** The meeting will be held on July 11, 2016, from 3:00 p.m.–5:00 p.m. EST.

**ADDRESSES:** This meeting will be held via teleconference. Teleconference information and the exact meeting time will be published closer to the meeting date at: <http://www.surgeongeneral.gov/priorities/prevention/advisorygrp/index.html>.

#### FOR FURTHER INFORMATION CONTACT:

Office of the Surgeon General, U.S. Department of Health and Human Services, 200 Independence Ave. SW.; Washington, DC 20201; 202-205-9517; [npcsupport@cdc.gov](mailto:npcsupport@cdc.gov).

**SUPPLEMENTARY INFORMATION:** The Advisory Group is a non-discretionary federal advisory committee that was initially established under Executive Order 13544, dated June 10, 2010, to comply with the statutes under Section 4001 of the Patient Protection and Affordable Care Act, Public Law 111-148. The Advisory Group was terminated on September 30, 2012, by Executive Order 13591, dated November 23, 2011. Authority for the Advisory Group to be re-established was given under Executive Order 13631, dated December 7, 2012. Authority for the Advisory Group to continue to operate until September 30, 2017, was given under Executive Order 13708, dated September 30, 2015.

The Advisory Group was established to assist in carrying out the mission of the National Prevention, Health Promotion, and Public Health Council (the Council). The Advisory Group provides recommendations and advice to the Council. It is authorized for the Advisory Group to consist of not more than 25 non-federal members. The Advisory Group currently has 21 members who were appointed by the President. The membership includes a diverse group of licensed health professionals, including integrative health practitioners who have expertise in (1) worksite health promotion; (2) community services, including community health centers; (3) preventive medicine; (4) health coaching; (5) public health education; (6) geriatrics; and (7) rehabilitation medicine.

A meeting description and relevant materials will be published closer to the meeting date at: <http://>

[www.surgeongeneral.gov/priorities/prevention/advisorygrp/](http://www.surgeongeneral.gov/priorities/prevention/advisorygrp/).

Members of the public have the opportunity to participate in the meeting and/or provide comments to the Advisory Group on July 11, 2016. Public comment will be limited to 3 minutes per speaker. Individuals who wish to participate in the meeting and/or provide comments must register by 12:00 p.m. EST on July 5, 2016. In order to register, individuals must send their full name and affiliation via email to [npcsupport@cdc.gov](mailto:npcsupport@cdc.gov). Individuals who need special assistance and/or accommodations, *i.e.*, sign language interpretation or other reasonable accommodations, should indicate so when they register. Members of the public who wish to have materials distributed to the Advisory Group members at these scheduled meetings should submit those materials when they register.

Dated: May 23, 2016.

**Brigitte Ulin,**

*Designated Federal Officer, Advisory Group on Prevention, Health Promotion, and Integrative and Public Health, Office of the Surgeon General.*

[FR Doc. 2016-13558 Filed 6-7-16; 8:45 am]

**BILLING CODE 4163-18-P**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### National Institutes of Health

#### Prospective Grant of an Exclusive License: The Development of an Anti-GPC3 Chimeric Antigen Receptor (CAR) Based on HN3 for the Treatment of Human Cancers

**AGENCY:** National Institutes of Health, Public Health Service, HHS.

**ACTION:** Notice.

**SUMMARY:** This notice, in accordance with 35 U.S.C. 209(c)(1) and 37 CFR Part 404.7(a)(1)(i), that the National Institutes of Health, Department of Health and Human Services, is contemplating the grant of an exclusive license to practice the inventions embodied in:

*Intellectual Property:*

U.S. Provisional Patent Application 61/477,020 entitled "Human Monoclonal Antibody Specific for Glypican-3 And Use Thereof" [HHS Ref. E-130-2011/0-US-01], PCT Patent Application PCT/US2012/034186 entitled "Human Monoclonal Antibodies Specific for Glypican-3 And Use Thereof" [HHS Ref. E-130-2011/0-PCT-02], Chinese Patent Application 201280029201.3 entitled "Human